Atea Pharmaceuticals, Inc. (AVIR) Operating cash flow 2018–2025
Atea Pharmaceuticals, Inc. (AVIR) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$132.0MFY2025 · since FY2018: -$7.9M → -$132.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$132.0M | +2.6% |
| FY2024 | -$135.5M | -58.7% |
| FY2023 | -$85.4M | +29.4% |
| FY2022 | -$121.0M | -39.1% |
| FY2021 | -$87.0M | -129.3% |
| FY2020 | $296.7M | +2413.0% |
| FY2019 | -$12.8M | -62.2% |
| FY2018 | -$7.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AVIR financial trends
AVIR RevenueAVIR Net incomeAVIR Net marginAVIR Gross profitAVIR Gross marginAVIR Operating incomeAVIR Operating marginAVIR Free cash flowAVIR Capital expendituresAVIR Return on equityAVIR Stock buybacksAVIR Dividends paidAVIR Total assetsAVIR Total liabilitiesAVIR Shareholders’ equityAVIR overview →